joining thanks you, for everyone And today's Thank call. David.
our the quarter our third of to demonstrate increased by weakest slightly third for over commitment revenue were seasonally XX% quarter XXXX and what of results strong typically compared quarter, second sales is financial our highlighted ongoing quarter to EksoHealth. for XXXX a third for record revenues objectives. up operational In the and achieving the the Our XXXX, of quarter quarter
margins, of improvement to an period from saw record last increased which XX% in a also up We gross in the year. same XX%,
to same compared continued XXXX. XX% in third a achieving XXXX the with quarter the have improve operating of period decrease We our expenses, in
our quarter to At cumulative the see customers and XX%, year-over-year QX, in rental adopting commercial strategy conversion yield our continues in rental achieved at Additionally, end strong reflects to improvement program of success of results. of sale our the metrics our the great the multiple rate third remains solutions. value our in financial a our the solid
noted customer established and in As and our quarter's provided last partners we to continue I on call, the awareness to to sales the shorten to EMEA regions cycle. the equip and extend our products channel support goal both effectively communicate better near-term value APAC the
implemented changes better are sales We our direct while Europe improving and in our by a expenses recent markets, that the results our our pleased operating are impact reducing partners. having we distribution supporting positive in
in Germany market experiencing our market a EMEA expect that play are mentioned, As role in we will direct significant in traction growth. the and
We European in of the to to key continue this potential realize evaluate strategies full our our region. products
QX Let U.S. and Revenue quarter our than customers. to our the EksoHealth. third increased now sales with XXXX, business higher by relative the beginning of me in XX% review more result to European segments, primarily
units. and XX converted units to two booked Ekso This comprising and seven rental that In units the third EksoNR sales. includes rented were units previously both EksoGT quarter, we
occurs. the market primary acute in focus Facility post As or and segment I our the have is past, IRF segment the Rehabilitation rehabilitation where much Inpatient discussed of acute
one rehab centers U.S. customers. XXXX XX% in the are of stork centers the EksoGT have roughly least U.S. eight rehab approximately Ekso at and of Today, XX top the
Facilities. Rehabilitation Inpatient to addition In
pilots new nursing segment also and are hospitals interest long-term SNIF and the We the are United seeing medical conditions treatment XX,XXX market LTAC the in and where with increased Long-Term on other There skilled XXX focus additional where or rehab the SNIFs facilities Acute States. Care is happening segments segment in on the of in about LTACs or long-term focus rehabilitation. in is
type therapy, our markets, on in post believe To we the is opportunity For aggregate IDNs of are roughly annually. gain operators. to $XXX share focused network acute $XXX million and robotic these market million we
in typically have our opportunities to facilitate multiple are have our believe play and various sales, multiunit that we operators represent currently increasingly purchase important processes. for provide decision-making complex they will XXX the at more process these adapting centers. power We customers sales growth We with who network an practices which strategy role approximately for stages
strategy increase of sales our to edge and our solidify is customer at important compliment the neuro per position both our cutting robotic leadership base customer our An rehabilitation. of to
device. EksoGT With generation the exoskeleton EksoUE extremity next the unveiling of our the portfolio our the and EksoNR, upper expansion to include of medical
of customers to growth focused we capacity in optimizing of and continued patients endurance achievements providing to reflect and commitment innovating ongoing driving remain underscore needs the everyday the human on ability strengths, These and and the customer XXXX sales superior serve address strive amplify enhancing our cost our that quarter service, for that by we Our third structure. mobility. motion activities our the solutions also and to
that interventions. were new Users our Group better the Annual PT feedback Clinical new of users particularly were implement information and clinical about software feedback to patient favorable. customers The early and many highly and feature was new hosted scores pleased ways at for enhancements we on treatment recently our excited the We meeting staff EksoNR’s this
allow Additionally, EksoGT sessions. quotes outstanding already installed with of for the our already outstanding in the field tracking represented has already existing of than an orders orders patient upgrades greater to translated base. U.S. Customer enthusiasm into outcome EksoGT’s existing quotes XX% over multiple measures EksoNR’s
participate sessions. them longer one-of-a-kind Our recently that and sessions, wearable in actively complete a more therapy greater patients of to motion to productive as increased gives device during range EksoUE is and ability tasks allowing
base In segment to addition our user represent an to EksoUE occupational who therapists new expand market. the exciting rehabilitation its include innovative within customer features
feedback number Our units. Patient is of focused where and activities has we a commercial placed excellent. have existing so clinician small been initial far customers on already
We continue expect QX we to XXXX QX unique about product market represents. the to through commercial this educate the and into activity XXXX ramp opportunity as
the economic already users our benefits solutions. recognize EksoGT clinical rehabilitation of and Our
We improve EksoUE outcomes. are communicating will and to a compelling patient them that clinical value proposition upgraded articulates the help workflows and how clearly the EksoNR their
strategy unit. an that will not position a they for providers yet the an of enhance Additionally, are because EksoUE our even their we can expanding important help if believe it offerings in complement base, customer patients our be EksoNR to purchase rehabilitation
with engage essential potential understanding with to for and to build our provides business. the trust salesforce another future customers it and securing reason Additionally, that is
a offerings product Going forward, continue to we patient outcomes. and clear evolve improving on focus improve will our with
ago, turn same now compared our year period lower a Works slower with customer were due me Let than industrial Ekso segment. to XXXX anticipated purchasing the for to quarter Revenues third primarily the decisions.
initial expected product is some as As longer noted, we and industrial processes. customers the rigorous they put evaluation than to adoption the we our of have qualification from been through somewhat time working with
about of the early several term the at opportunities are optimistic potential offerings, we stage. industrial remain our While longer customer
mix a as on a and our broader updating industrial advance. programs outside initial are with look of We of discussions, markets in a including industries diversification forward construction engage progress the our variety to you companies customer I and of go-to-market, taking steps pilot in strategies segments. segments to
industrial In China with products of expect end manufacturer China, production XXXX we our commence shipments of the the transferring first are to for of a and industrial in XXXX. the partner to in to the before process JV quarter as qualify JV our anticipated
Ekso our and important in achieve of follow JV strategies Devices additional of shipments Medical Initiating shipments Bionics improve our to expected to from operational milestone efficiencies. goods shortly thereafter. qualification Production is are the cost an Ekso
will China. Additionally, JV regulatory achieving capability pursue compliance, to the which EksoNR to and allow required medical China device in production market sell is the
concludes opening remarks. That my
over to our Now I turn third results. financial XXXX to quarter the will review Jack call
